MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).

MaaT Pharma, a biotech focused on restoring and modulating patient-microbiome symbiosis for the treatment of cancer, also spoke with pharmaphorum. A spokesperson for the company explained why the ...

Shares of NATCO Pharma tumbled another 10% in intra-day trade on Friday, February 14, extending its slide to the sixth straight session. The stock had tumbled 20% on Thursday as well following the ...

The pharmaceutical firm’s consolidated revenue from operations fell to ₹474.8 crore in Q3 FY2025, down from ₹758.6 crore in the year-ago period, reflecting a 37.4 percent decrease in ...

From industry-specific AI to the rise of AI agents, here are four trends set to disrupt pharma and healthcare in 2025. AI helps pharma truly put patients and HCPs first Over the past two years ...

UroGen Pharma (URGN) highlighted results from a long-term follow-up study with Jelmyto for pyelocalyceal solution, which is FDA approved for the treatment of low-grade, upper tract urothelial ...

Kairos Pharma (KAPA) announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah for the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.

While Kennedy may not follow through on policy ambitions to ban direct-to-consumer (DTC) advertising, for example, he still has the power to be “extraordinarily influential” on pharma, according to ...

Natco Pharma Ltd has received final approval from the USFDA to market Bosentan 32mg tablets. This drug, Bosentan 32mg tablets is used for the treatment of pulmonary arterial hypertension (PAH).

Valentine’s Day represents a perfect opportunity to highlight news and updates from across biopharma that have hearts all aflutter. In this week’s episode of “The Top Line,” we do just ...

On the other hand, West Pharmaceutical Services narrowly topped analysts' revenue expectations, signaling resilience in key markets like Biologics and Pharma. However, its forecast suggests ...

LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the ...